Last reviewed · How we verify
Calculus in biliary tract — Treatment Landscape & Competitive Intelligence
4 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cholbam | CHOLIC ACID | Mirum | Bile Acid [EPC] | G-protein coupled bile acid receptor 1 | 2015-01-01 | |
| Actigall | URSODIOL | AbbVie | Bile Acid [EPC] | CDGSH iron-sulfur domain-containing protein 1 | 1987-01-01 | |
| Cholbam | Cholbam | Mirum Pharmaceuticals, Inc. | G-protein coupled bile acid receptor 1, Bile acid receptor | |||
| Ursolvan | Ursolvan | Hopital Foch | Aldo-keto reductase family 1 member C2, CDGSH iron-sulfur domain-containing protein 1, Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Calculus in biliary tract
- AbbVie · 1 drug in Calculus in biliary tract
- Hopital Foch · 1 drug in Calculus in biliary tract
- Mirum · 1 drug in Calculus in biliary tract
- Mirum Pharmaceuticals, Inc. · 1 drug in Calculus in biliary tract
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Calculus in biliary tract:
- Calculus in biliary tract treatment updates — RSS
- Calculus in biliary tract treatment updates — Atom
- Calculus in biliary tract treatment updates — JSON
Cite this brief
Drug Landscape (2026). Calculus in biliary tract — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/calculus-in-biliary-tract. Accessed 2026-06-10.
Related
- Calculus in biliary tract full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing